Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated By Epigenetic Plasticity of Residual Disease and By-Pass Signaling Via MAPK PathwayLodovico Terzi di Bergamo, Davide Rossi, Alessio Bruscaggin et al.|Blood|2024Cited by 4
ADAPTATION OF CHRONIC LYMPHOCYTIC LEUKEMIA TO IBRUTINIB IS MEDIATED BY EPIGENETIC PLASTICITY OF RESIDUAL DISEASE AND BY‐PASS SIGNALING VIA MAPK PATHWAYLodovico Terzi di Bergamo, Davide Rossi, Gabriela Forestieri et al.|Hematological Oncology|2021Cited by 1
CLL-358: Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated by Epigenetic Plasticity of Residual Disease and Bypass Signaling via the MAPK PathwayLodovico Terzi di Bergamo, Davide Rossi, Gabriela Forestieri et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 1
Poster: CLL-358: Adaptation of Chronic Lymphocytic Leukemia to Ibrutinib Is Mediated by Epigenetic Plasticity of Residual Disease and Bypass Signaling via the MAPK PathwayLodovico Terzi di Bergamo, Davide Rossi, Gabriela Forestieri et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 0